Several modes of reperfusion therapy for evolving myocardial infarction (MI) have been
developed, which differ in terms of effectiveness, complexity and costs. Reperfusion …

Streptokinase and urokinase have proved to be useful in a limited number of clinical
conditions. Mainly because of the risk and unpredictability of bleeding with this first …

Three thrombolytic agents are frequently used in the United States for treating patients with
acute myocardial infarction: streptokinase, alteplase (tissue plasminogen activator [t-PA]) …

Trials of thrombolytic therapy have taught us that 1) lysis of hemostatic plugs, not
fibrinogenolysis, is the major cause of bleeding complications; 2) as currently reported …

Several trials enrolling thousands of patients have demonstrated the beneficial effect of
thrombolytic therapy on survival in patients with acute myocardial infarction. Three large …

The value of coronary artery reperfusion resulting from pharmacologically induced
fibrinolysis in patients with evolving myocardial infarction has been rigorously evaluated …

Coronary thrombolysis revolutionized the treatment of acute myocardial infarction. Most of
the experience was obtained with intravenous use of streptokinase and tissue‐type …

It started in 1983, when the GISSI-1 (Gruppo Italiano per lo Studio della Streptochinasi
nell'Infarcto Miocardico) investigators decided to set up their unique study in 176 coronary …

There is now a general consensus based on the results of coronary angiography and heart
surgery that, in the early stage of transmural myocardial infarction, an occlusion of an infarct …

Thrombolytic therapy has become the mainstay of treatment for acute transmural myocardial
infarction. The current guidelines recommend that thrombolytic therapy be administered to …